CClinicalTrials.gg
CompletedNCT07571382COVID-19Updated May 6, 2026

Post-Covid-19 Patients Follow-up Study

An interventional study of Smell training in Smell Dysfunction, Taste Dysfunction and Trigeminal Dysfunction, sponsored by University of Oslo. Completed at 1 site in Norway. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by University of Oslo · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
176
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Taste, smell, trigeminal and salivary function is impacted in post-COVID-19 patients

02

Conditions studied

  • Smell Dysfunction
  • Taste Dysfunction
  • Trigeminal Dysfunction
  • Salivary Dysfunction

Keywords

  • Smell
  • Taste
  • Trigeminus
  • Salivation
03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

-COVID-19 diagnosis

Exclusion criteria

Exclusion Criteria:

-Not COVID-19 diagnosis

04

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
176 participants (actual)

Study arms

  • Other
    Parosmia

    Parosmia

    Other: Smell training

Interventions

  • OtherSmell training

    Smell training

05

What researchers measure

Primary outcomes

  1. Smell

    Olfactory (smell) function will be evaluated using the Twelve felt-tip Sniffin' Sticks test (Burghart Messtechnik GmbH, Holm, Germany). Participants are categorized into anosmic (score 0-6, no smell), hyposmic (score 7-10, reduced smell), and normosmic (score 11-12, normal smell), according to normative classification.

    Time frame: two years

Secondary outcomes

  1. Taste

    Gustatory (taste) function is assessed using Taste Strips impregnated with solutions of four different taste qualities (sweet, sour, salty, and bitter) in four different concentrations (Burghart Messtechnik GmbH, Holm, Germany). Participants are classified into ageusic (score 0, no taste), hypogeusic (score 1-8, reduced taste) and normogeusic (score 9-16, normal taste) using a normative classification. Participants are considered to have a specific ageusia if they are unable to detect all four different concentrations of a particular tastant.

    Time frame: 2 years

  2. Dry mouth

    Xerostomia (oral dryness) iss categorized according to participants' self-reported perception as either no dry mouth (score 0), or dry mouth (score 1). Participants are asked whether the symptoms of xerostomia started before or after COVID-19 infection and are asked open-ended questions where they could describe their experience of oral dryness. Finally, they are asked to report whether there are food items that they had to refrain from eating because of parosmia, dysgeusia, dysesthesia or xerostomia.

    Time frame: 2 years

  3. Dysesthesia

    Dysesthesia (oral burning sensation) iss categorized as either no dysesthesia (score 0), or dysesthesia (score 1). Participants report how often they experienced dysesthesia (constantly, daily, sometimes, periodically, during meals, in between meals), asked to describe where in the mouth they experienced dysesthesia (whole tongue, anterior tongue, lips, palate, buccal mucosa, other), and identify food items that enhanced the dysesthesia (spicy, sweet, sour, salty, bitter).

    Time frame: 2 years

06

Study locations

1 site
  • University of Oslo
    Oslo, Oslo 0455, Norway
07

References and documents

Study documents

  • Study protocol · Jul 1, 2021

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT07571382
Lead sponsor
University of Oslo
Responsible party
Per Ole Iversen, MD (Professor, University of Oslo) — Principal investigator
First posted
May 6, 2026
Start date
Apr 1, 2021
Primary completion
Apr 25, 2023
Completion
Apr 25, 2023
Last update
May 6, 2026

Study contacts

Per Ole Iversen, PhD
principal investigator · Per Ole Iversen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion